ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Highly-sensitized"

  • 2020 American Transplant Congress

    Accommodating Increasing Volumes without Knocking Down Walls: Update on an Infusion Center’s Growth

    J. C. Estrada

    Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA

    *Purpose: An increase in transplants performed at the medical center in comparison to the limited availability of outpatient infusion chairs and home infusion companies compelled…
  • 2020 American Transplant Congress

    Risk Factors for Antibody-Mediated Rejection after Adult Liver Transplantation with Preformed Donor-Specific Antibodies: A Single Center Experience

    T. Tajima, K. Hata, J. Kusakabe, H. Miyauchi, T. Anazawa, T. Ito, S. Uemoto

    Div. of HBP Surgery and Transplantation, Dept. of Surgery, Kyoto University, Kyoto, Japan

    *Purpose: In general, preformed donor-specific antibodies (pDSAs) can lead to an increased risk of antibody-mediated rejection (AMR); however, their prevalence, risk factors, and the efficacy…
  • 2020 American Transplant Congress

    Desensitization Combining Costimulation Blockade with Proteasome Inhibition in Highly Sensitized Transplant Candidates

    S. Restaino1, D. Jennings2, G. Serban3, E. Vasilescu3, G. Sayer1, N. Uriel1, K. Takeda4, Y. Naka4, M. Farr1, M. V. Habal1

    1Cardiology, Columbia University Irving Medical Center, New York, NY, 2School of Nursing, Columbia University Irving Medical Center, New York, NY, 3Pathology&Cell Biology, Columbia University Irving Medical Center, New York, NY, 4Cardiothoracic Surgery, Columbia University Irving Medical Center, New York, NY

    *Purpose: Antibodies to human leukocyte antigens (HLA) pose a significant barrier to transplantation. Strategies to reduce allosensitization have modest efficacy and may result in antibody…
  • 2020 American Transplant Congress

    Kidneys from Pediatric Donors Are Preferentially Allocated to Adult Highly Sensitized and Not to Pediatrics Under the New Kidney Allocation System (KAS)

    D. Puliyanda1, H. Pizzo1, J. Garrison1, S. Williamson2, I. Kim2, E. Huang2

    1Pediatric Nephrology, Cedars-Sinai Medical Center, Los Angeles, CA, 2Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

    *Purpose: In 12/2014, the new Kidney Allocation System (KAS) assigned allocation priority to highly sensitized (HS) recipients while maintaining access to donors for pediatric patients…
  • 2020 American Transplant Congress

    Blocking Complement Component C3 in a Sensitized Nonhuman Primate Model of Kidney Allotransplantation

    R. Schmitz1, P. M. Schroder1, Z. W. Fitch1, A. Y. Choi1, M. Manook1, J. Yoon1, A. Farris2, E. S. Reis3, J. D. Lambris3, J. Kwun1, S. J. Knechtle1

    1Department of Surgery, Duke University Medical Center, Durham, NC, 2Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, 3Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

    *Purpose: Sensitized transplant recipients represent a challenge due to the presence of donor-specific antibodies (DSA), which increase the risk of antibody-mediated rejection. Complement inhibition has…
  • 2020 American Transplant Congress

    Outcomes of HLAi Transplant in CPRA 98-100 after Desensitization: Single Center Experience

    A. Vo1, E. Huang1, M. Haas2, S. Williamson1, C. Meyers1, A. Peng1, R. Najjar1, S. Sethi1, N. Ammerman1, K. Lim1, M. Gillespie1, S. C. Jordan1

    1Cedars Sinai Medical Ctr, Los Angeles, CA, 2Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA

    *Purpose: The new KAS implementation aimed at increasing equity in organ allocation for broadly sensitized (HS) patients. However, recent data shows that for the most…
  • 2020 American Transplant Congress

    Third and Fourth Kidney Re-Transplants: A 20-Year Single Centre Experience

    O. O. Okidi1, A. Hassan1, S. Bhutani1, A. Summers1, K. Poulton2, C. Fullwood1, D. VanDellen1, J. Worthington2, T. Augustine1

    1Transplant and Endocrine Surgery, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom, 2Transplantation Laboratory, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, United Kingdom

    *Purpose: Re-transplantation may be associated with management dilemmas including repeat allocation of limited kidney allografts to same individuals in the face of an increasing waiting…
  • 2020 American Transplant Congress

    Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment

    A. Runström1, R. Bockermann1, K. Sjöholm1, K. M. Roupé1, Å. Schiött1, L. Winstedt1, C. Kjellman1, T. Lorant2

    1Hansa Biopharma AB, Lund, Sweden, 2Section of Transplantation Surgery, Department of Surgical Sciences, Uppsala, Sweden

    *Purpose: The immunoglobulin G (IgG)-degrading cysteine protease, imlifidase (IdeS) is an IgG endopeptidase under development as a rapid desensitization treatment in kidney transplantation. Imlifidase is…
  • 2020 American Transplant Congress

    Outcomes of Post-Transplant Desensitization in High Immunological Risk Deceased Donor Kidney Transplant Recipients

    D. Kumar, C. Song, L. Kamal, I. Moinuddin, M. Levy, C. Bhati, A. King, P. Kimball, G. Gupta

    Virginia Commonwealth University, Richmond, VA

    *Purpose: The kidney allocation system (KAS) was changed in 2015 to increase access to transplants for highly sensitized patients. However, recent data suggests that even…
  • 2020 American Transplant Congress

    Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up

    A. A. Vo1, N. Ammerman1, E. Huang1, M. Toyoda2, S. Ge2, A. Peng1, R. Najjar1, S. Williamson1, C. Meyers1, S. Sethi1, K. Lim1, J. Choi1, S. C. Jordan1

    1Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, 2Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA

    *Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences